Janet Woodcock News
-
Pharmacyclics Inc., a drugmaker developing an experimental therapy for blood cancers, rose to its highest level in more than a decade after gaining “breakthrough” status from U.S. regulators.
-
Pharmacyclics Inc., a drugmaker developing an experimental therapy for blood cancers, won “breakthrough” status from U.S. regulators for the medicine that may lead to quicker marketing approval.
-
Drugmakers may win approval from U.S. regulators for “breakthrough” therapies after a single round of studies, rather than three, in an effort to speed them to patients, a Food and Drug Administration official said.
-
April Hauge, a nurse practitioner in Weimar, California, spent $500 on a genetic test for her autistic son in 2009 that led to purchasing thousands of dollars in vitamins and supplements. Impressed with the results, she’s now selling advice on the approach to others.
-
Half of the 21 drugs pulled from the market in the U.S. for safety reasons since 1995 involved heart complications, a finding that is spurring Congress and doctors to call for closer government review of side effects.
-
The Food and Drug Administration is weighing whether to let consumers buy medicines for some chronic conditions without a prescription while speeding approvals of drugs for infection, Alzheimer’s disease and rare conditions.
-
Roche Holding AG ’s top-selling drug Avastin should no longer be used to treat breast cancer after recent studies failed to show a benefit, U.S. regulators said.
-
Drug cocktails for cancer, heart disease and other conditions may reach the U.S. market sooner under new guidelines that let companies seek approval for a combination of two or more medicines at the same time.
-
When Apostolia M. Tsimberidou was a young hematologist, a diagnosis of chronic myelogenous leukemia meant a patient had only a few years to live.
-
Pfizer Inc. , Johnson & Johnson and Endo Pharmaceuticals Holdings Inc. will have to train doctors before they can give patients extended-release painkillers under a U.S. plan aimed at reducing prescription drug abuse.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page